Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors (NCT05856981)
An Open-Label, Multicenter, Multi-arm Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1805 in Adults With Advanced Solid Tumors
๐ฉบ Plain-English Summary (8th-Grade Level)
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPฮฑ monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).
Who can join: Review the eligibility criteria below.
Location: Henry Ford Cancer Institute โ Detroit, Michigan
Age range: 18 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (7 Sites)
- Henry Ford Cancer Institute โ Detroit, Michigan
- Washington University Medical Campus โ St Louis, Missouri
- Gabrail Cancer & Research Center โ Canton, Ohio
- Virginia Cancer Specialists โ Fairfax, Virginia
- Grand Hopital de Charleroi (GHdC) - Hopital Notre Dame โ Charleroi,
- Hosp 12 de Octubre โ Madrid,
- Hospital General Universitario Gergorio Maranon โ Madrid,
๐ Contact the Study Coordinator
Phone: 0031 85 90 26 939
Email: clinical@sairopa.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor, Adult
- A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody โ Sarasota, Florida
- First-in-Human Study of ICT01 in Patients With Advanced Cancer โ Gilbert, Arizona
- A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors โ Los Angeles, California
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab โ Los Angeles, California
- A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial โ Scottsdale, Arizona
- A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression โ Gilbert, Arizona
Explore by condition: All Solid Tumor, Adult clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.